Results 11 to 20 of about 64,945 (43)

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer [PDF]

, 2013
Background: Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR) of 10-15%.
Arnold, Dirk, Dellas, Kathrin, Dunst, Jürgen, Engel, Erik, Höhler, Thomas, Reese, Thomas, Richter, Michael, Rödel, Claus, Wagner, Wolfgang, Würschmidt, Florian   +9 more
core   +1 more source

Metformin: a modulator of bevacizumab activity in cancer? A case report. [PDF]

, 2015
Recurrent type I endometrial cancer ((EC)) has poor prognosis and demands novel therapeutic approaches. Bevacizumab, a VEGF-A neutralizing monoclonal antibody, has shown clinical activity in this setting. To our knowledge, however, although some diabetic
Aliberti, C, Casarin, A, Indraccolo, Stefano, Nardin, M, Nicoletto, Mo, Pomerri, Fabio, Randon, G, Zulato, E   +7 more
core   +1 more source

European medicines agency approval summary: zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer [PDF]

, 2017
On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap) in combination with irinotecan/5-fluorouracil/ folinic acid chemotherapy for the treatment of adults with metastatic colorectal cancer ...
Caleno, Mariapaola, Foggi, Paolo, Gravanis, Iordanis, Melchiorri, Daniela, Pignatti, Francesco, Salmonson, Tomas, Sjöberg, Jan, Stanel, Stefan Cristian, Tzogani, Kyriaki   +8 more
core   +1 more source

Adverse events associated with intraocular injection of anti-VEGF(bevacizumab) in retinal vein ccclusion: a case report [PDF]

, 2015
Introduction: Antiangiogenic agents are often administered for treatment of Branch Retinal Vein Occlusion (BRVO). Among them, Bevacizumab has noticeable antiangiogenic and antiedemigenic properties and possesses great capacity to penetrate the retinal ...
ARTICO, Marco, BOTTONE, Andrea, Domenica Piraino, Carmen, Mollicone, Antonella, PACELLA, Elena, PACELLA, FERNANDA, Romana Parisiella, Francesca, TURCHETTI, PAOLO   +7 more
core   +1 more source

Bowel Perforation in the Emergency Department Related to Bevacizumab Therapy and Recurrent Ovarian Cancer [PDF]

, 2020
Case Presentation: We describe the presentation to the emergency department of a patient with recurrent ovarian cancer treated with bevacizumab with the complication of bowel perforation.
Burleson, Samuel L., Leath III, Charles A., Olushoga, Michael, Ostby, Stuart A.   +3 more
core  

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO [PDF]

, 2018
Right-sided metastatic colorectal cancer (mCRC) patients have poor prognosis and achieve limited benefit from first-line doublets plus a targeted agent.
Allegrini, G, Antoniotti, C, Bergamo, F, Boni, L, Buonadonna, A, Cortesi, E, Cremolini, C, Falcone, A, Fontanini, G, Granetto, C, Lonardi, S, Loupakis, F, Marmorino, F, Masi, G, Moretto, R, Racca, P, Ronzoni, M, Sensi, E, Tomasello, G, Tonini, G, Zagonel, V, Zaniboni, A   +21 more
core   +3 more sources

Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion [PDF]

, 2008
Purpose: To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion.Methods: A prospective, non-comparative ...
Alge, C. S., Burger, J., Haritoglou, Christos, Kampik, Anselm, Kook, Daniel, Kreutzer, Thomas C., Kunze, C., Priglinger, Siegfried, Strauss, R., Wolf, A. H.   +9 more
core   +1 more source

Cost effectiveness of treatments for wet age-related macular degeneration [PDF]

, 2011
Age-related macular degeneration (AMD) is a leading cause of blindness in people aged >= 50 years. Wet AMD in particular has a major impact on patient quality of life and imposes substantial burdens on healthcare systems.
Annemans, Lieven, Gallagher, Meghan, Mitchell, Paul, Thomas, Simu, White, Richard   +4 more
core   +1 more source

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal, Buyse, Marc E., Conlin, Alison K., Geyer, Charles E., Jr., Gross, Howard M., Jacobs, Samuel A., Keogh, George P., Lord, Raymond S., Mamounas, Eleftherios P., Mauquoi, Celine, Patocskai, Erica J., Polikoff, Jonathan A., Rastogi, Priya, Robidoux, André, Smith, John W., Stella, Philip J., Swain, Sandra M., Wolmark, Norman   +17 more
core   +2 more sources

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. [PDF]

, 2018
BackgroundContinuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer.
Bedford, Rudolph, Donahue, Timothy, Hines, O Joe, Hoos, William, Isacoff, William H, Rahib, Lola, Reber, Howard A, Upfill-Brown, Alexander   +7 more
core   +1 more source